Abstract
This randomized, blinded, sham-controlled trial evaluated the efficacy of navigation-guided repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex (M1) in 30 patients with chronic upper limb neuropathic pain. The protocol involved five daily sessions followed by weekly maintenance for seven weeks. While the primary outcome—reduction in daily pain intensity at week 9—did not reach statistical significance compared to sham, the active rTMS group showed significant improvements in pain-related disability. The treatment was well-tolerated with no serious adverse events, suggesting rTMS may enhance functional outcomes in this patient population.
Introduction
Neuropathic pain, affecting approximately 10% of the population, remains a significant clinical challenge due to its resistance to conventional pharmacological and surgical treatments. Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex (M1) has emerged as a promising non-invasive neuromodulation technique. Previous research suggested that neuropathic pain in the upper limbs might be particularly responsive to cortical stimulation. This study aimed to rigorously test a high-dose, long-term rTMS protocol specifically tailored for patients with upper limb neuropathic pain.
Methods
The study was a randomized, patient- and assessor-blinded, sham-controlled parallel trial conducted at Osaka University Hospital. Thirty patients with chronic neuropathic pain (baseline score $\ge$ 4/10) were randomized into active rTMS (n=14) or sham-stimulation (n=16) groups.
Intervention Protocol
The active group received 10-Hz rTMS (2000 pulses/session) targeting the M1 hand area, guided by a navigation system. The protocol was divided into an intensive induction phase and a maintenance phase.
To maintain blinding, the sham group received stimulation from an identical-looking coil and simultaneous low-current electrical scalp stimulation to mimic the physical sensation of active rTMS—a rigorous control often missing in earlier studies.
Results
The primary outcome was the change in the weekly average of a daily pain diary (Numerical Rating Scale) at week 9.
Pain Intensity and Patient Impression
While both groups showed a downward trend in pain scores, the difference between the active group (0.84 ± 0.31 reduction) and the sham group (0.58 ± 0.29 reduction) was not statistically significant ($p = 0.54$). However, early in the treatment (Day 5), the active group reported significantly higher rates of "minimal improvement" on the Patient Global Impression of Change (PGIC) scale (36% vs. 19%, $p = 0.04$).
Functional Improvement
Despite the lack of significant sensory pain relief, the active group demonstrated a statistically significant improvement in the Pain Disability Assessment Scale (PDAS). The active group showed a mean improvement of 8.0 points compared to -0.3 in the sham group ($p = 0.03$). This suggests a "function over feeling" effect, where neuromodulation helps patients manage daily activities better despite persistent pain intensity.
Discussion
The study's failure to meet its primary endpoint may be attributed to several factors, including a small sample size and a potentially over-effective sham control. The use of electrical scalp stimulation in the sham group may have activated "gate control" mechanisms, narrowing the gap between groups. Nevertheless, the significant improvement in pain-related disability is a clinically meaningful finding. Future research should utilize larger cohorts and longer intervention periods to further explore the functional benefits of rTMS in chronic pain management.
Summary updated